- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-AKT2 monoclonal antibody
Pre-made anti-AKT2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to AKT2/AKT2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T94621-Ab-1/ GM-Tg-hg-T94621-Ab-2 | Anti-Human AKT2 monoclonal antibody | Human |
| GM-Tg-rg-T94621-Ab-1/ GM-Tg-rg-T94621-Ab-2 | Anti-Rat AKT2 monoclonal antibody | Rat |
| GM-Tg-mg-T94621-Ab-1/ GM-Tg-mg-T94621-Ab-2 | Anti-Mouse AKT2 monoclonal antibody | Mouse |
| GM-Tg-cynog-T94621-Ab-1/ GM-Tg-cynog-T94621-Ab-2 | Anti-Cynomolgus/ Rhesus macaque AKT2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T94621-Ab-1/ GM-Tg-felg-T94621-Ab-2 | Anti-Feline AKT2 monoclonal antibody | Feline |
| GM-Tg-cang-T94621-Ab-1/ GM-Tg-cang-T94621-Ab-2 | Anti-Canine AKT2 monoclonal antibody | Canine |
| GM-Tg-bovg-T94621-Ab-1/ GM-Tg-bovg-T94621-Ab-2 | Anti-Bovine AKT2 monoclonal antibody | Bovine |
| GM-Tg-equg-T94621-Ab-1/ GM-Tg-equg-T94621-Ab-2 | Anti-Equine AKT2 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T94621-Ab-1/ GM-Tg-hg-T94621-Ab-2; GM-Tg-rg-T94621-Ab-1/ GM-Tg-rg-T94621-Ab-2; GM-Tg-mg-T94621-Ab-1/ GM-Tg-mg-T94621-Ab-2; GM-Tg-cynog-T94621-Ab-1/ GM-Tg-cynog-T94621-Ab-2; GM-Tg-felg-T94621-Ab-1/ GM-Tg-felg-T94621-Ab-2; GM-Tg-cang-T94621-Ab-1/ GM-Tg-cang-T94621-Ab-2; GM-Tg-bovg-T94621-Ab-1/ GM-Tg-bovg-T94621-Ab-2; GM-Tg-equg-T94621-Ab-1/ GM-Tg-equg-T94621-Ab-2 |
| Products Name | Anti-AKT2 monoclonal antibody |
| Format | mab |
| Target Name | AKT2 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-AKT2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-T94621-Ag-1 | Recombinant multi-species AKT2/ HIHGHH/ PKBB protein |
| ORF Viral Vector | pGMLV000359 | human AKT2 Lentivirus plasmid |
| ORF Viral Vector | vGMLV000359 | human AKT2 Lentivirus particle |
| ORF Viral Vector | pGMAD000122 | mouse Akt2 Adenovirus plasmid |
| ORF Viral Vector | pGMAD000436 | house mouse Akt2 Adenovirus plasmid |
| ORF Viral Vector | pGMAAV000144 | mouse Akt2 AAV plasmid |
| ORF Viral Vector | pGMAAV000152 | mouse Akt2 AAV plasmid |
| ORF Viral Vector | vGMAD000122 | mouse Akt2 Adenovirus particle |
| ORF Viral Vector | vGMAD000436 | house mouse Akt2 Adenovirus particle |
| ORF Viral Vector | vGMAAV000144 | mouse Akt2 AAV particle |
| ORF Viral Vector | vGMAAV000152 | mouse Akt2 AAV particle |
Target information
| Target ID | GM-T94621 |
| Target Name | AKT2 |
| Gene ID | 208,11652,25233,700591,449021,100499544,534923,100064671 |
| Gene Symbol and Synonyms | 2410016A19Rik,AKT2,HIHGHH,PKB,PKBB,PKBBETA,PRKBB,RAC-BETA |
| Uniprot Accession | P31751,P47197 |
| Uniprot Entry Name | AKT2_HUMAN,AKT2_RAT |
| Protein Sub-location | Introcelluar Protein |
| Category | Therapeutics Target |
| Disease | Cancer |
| Gene Ensembl | ENSG00000105221 |
| Target Classification | Kinase, Tumor-associated antigen (TAA) |
The target: AKT2, gene name: AKT2, also named as HIHGHH, PKBB, PKBBETA, PRKBB, RAC-BETA. This gene is a putative oncogene encoding a protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains, which is involved in signaling pathways. The gene serves as an oncogene in the tumorigenesis of cancer cells For example, its overexpression contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. The encoded protein is a general protein kinase capable of phophorylating several known proteins, and has also been implicated in insulin signaling. [provided by RefSeq, Nov 2019].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
